A Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma

Trial Information
Eligibility
Locations
Next steps

Active, Not Recruiting

Trial Purpose

The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. The study will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation.

View full trial information on Clinicaltrials.gov

	National Trial Reference Number	NCT05468697
	MSD Protocol ID	MK-6482-024
	Conditions	Renal Cell Carcinoma
	Age Range	18+
	Sex	ALL
	Trial Phase	1, 2
	Start Date End Date	2022-08-10 2026-07-21

Study Details

Patient Participation

Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial.

Conditions

Renal Cell Carcinoma

View full trial eligibility

Trial Phase 1

Investigational medication is tested for safety on a relatively small group of 20 to 100 volunteers who are usually healthy, but not always. Phase 1 trials may happen in a doctor’s office or a hospital.

Trial Phase 2

In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.

View full trial information on Clinicaltrials.gov

Trial Locations

Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.

Sorry, there are no locations found.

What can you do next?

If you think this clinical trial might be a good fir and you are interested in taking part, take the next step to see if you are eligible.

Discuss with your doctor or care team

Print this page with details about the trial or email it to your doctor to discuss the clinical trial during your next visit.

Get help talking with your doctor or care team

Print Email

Contact our Trial Information Center

To learn more, call 1-888-577-8839

Taking part in a clinical trial is an important decision

If you are considering joining a clinical trial, first learn as much as you can about:

The investigational treatment that is being studied
What the risks and possible benefits are for participants

Talk to your doctor about the clinical trial before you decide to join.

Read our “What to Consider” page for more questions to ask and think about

Clinicaltrials.gov Identifier

NCT05468697

When you talk with your doctor or clinical trial team member, please have the trial identifier number or the EudraCT number available.